Tysabri and PML: What Are the Key Symptoms and Monitoring Steps?
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
Legacy of General Health Information and Transition to Targeted Risk Assessment
If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, vision changes, or weakness, you may be concerned about progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that early detection through laboratory testing, including the anti-JCV antibody index (LA testing), is critical for managing this rare but serious condition. This page explains the symptoms to watch for, how LA testing and evaluation work, and what the current medical guidelines recommend for monitoring.
Medical Overview of Tysabri and Progressive Multifocal Leukoencephalopathy
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling and clinical data to outline the medical facts, risk factors, and settlement-related considerations for affected patients. Clinical Presentation and Diagnosis of PML Progressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caused by reactivation of the JC virus. In immunocompromised individuals, the virus infects oligodendrocytes, leading to progressive neurological deficits. Clinical presentation typically includes subacute onset of focal neurological symptoms such as hemiparesis, visual field defects, ataxia, cognitive decline, and speech disturbances. Diagnosis relies on brain MRI showing multifocal white matter lesions without mass effect, and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. Brain biopsy may be confirmatory in ambiguous cases. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri Pharmacology and Reported Adverse Effects Tysabri is a humanized monoclonal antibody that binds to alpha-4 integrin, inhibiting leukocyte adhesion and migration across the blood-brain barrier. This mechanism reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance in the central nervous system, creating a permissive environment for JC virus reactivation. In clinical trials, PML occurred in three patients who received Tysabri: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, toothache, infections (sinusitis, vaginal infections, viral infection), cough, lower abdominal pain, back pain, and dysmenorrhea (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Adequacy of Warnings and Settlement-Related Considerations
The prescribing information for Tysabri includes a boxed warning stating that the drug increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies risk factors and instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients have developed PML, leading to lawsuits alleging inadequate risk communication. Patients who develop PML after Tysabri treatment may pursue legal claims based on failure to warn, product liability, or negligence. Settlement criteria typically consider the presence of anti-JCV antibodies, duration of therapy, prior immunosuppressant use, and whether the patient was monitored according to guidelines. The timeline between exposure and documented harm is critical: PML can occur after as few as eight doses (in Crohn's disease) or after prolonged treatment beyond two years (in multiple sclerosis) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Medical records documenting the date of first Tysabri infusion, the onset of neurological symptoms, and the date of PML diagnosis are essential for establishing causation. Settlements may cover medical expenses, lost income, pain and suffering, and long-term care costs. Patients should consult legal counsel experienced in pharmaceutical litigation to evaluate individual case merits.
Timeline Between Exposure and Documented Harm
In clinical trials, PML occurred in multiple sclerosis patients after a median of 120 weeks of treatment, and in one Crohn's disease patient after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that risk increases with longer exposure, particularly beyond two years. The latency period from JC virus reactivation to clinical symptoms can be weeks to months, and early diagnosis via MRI and CSF analysis is critical for improving outcomes. Patients who develop PML typically experience rapid neurological deterioration, and the condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Tysabri and why is it associated with PML?
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of inhibiting immune cell trafficking into the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the settlement criteria for Tysabri-related PML lawsuits?
Settlement criteria typically include documented Tysabri exposure, confirmed PML diagnosis, presence of risk factors (anti-JCV antibodies, treatment duration >2 years, prior immunosuppressant use), and evidence that monitoring guidelines were not followed. Medical records showing the timeline from first infusion to symptom onset and diagnosis are essential (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.